Background {#Sec1}
==========

The widespread emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) could limit the globally declining trend in tuberculosis (TB) prevalence that has been observed in recent years. It is estimated that worldwide 20 % of previously treated TB cases and 3.3 % of new TB cases now have multidrug-resistant tuberculosis -- caused by bacterial strains resistant to at least isoniazid and rifampicin \[[@CR1]\].

Treatment for MDR-TB and XDR-TB currently entails therapeutic regimens with much lower efficacy and greater toxicity than those used for drug-susceptible TB. Successful treatment outcome was only reported for 50 % of MDR-TB patients globally in 2014, compared to 86 % for newly diagnosed drug susceptible disease \[[@CR1]\], and second line agents commonly used are poorly tolerated. Current recommendations for treatment of MDR-TB require at least 20 months of therapy \[[@CR2]\], though mounting evidence indicates that shorter regimens may perform at least as well \[[@CR3]\].

Early treatment of MDR-TB is presumed to be associated with improved treatment outcomes, yet the evidence in support of this assumption has not been previously reviewed. Individuals with a prolonged delay to treatment are perceived as more likely to have a higher bacillary burden, more extensive lung damage and, as a result, active TB disease that is harder to treat. With the introduction of rapid diagnostic tools and reported reductions in time to identification and treatment of MDR-TB in many settings, there is interest in determining whether such reductions are associated downstream with improved MDR-TB treatment outcomes. Moreover some countries are struggling to keep up with the demand for MDR treatment as they diagnose more and more cases, creating "waiting lists" wherein patients have to wait until treatment capacity is available. Demonstration of an adverse effect upon patient outcome of such delays would be a potentially useful tool for strengthened advocacy to promote interventions that enhance linkage of test results to treatment.

We therefore undertook a systematic review of the existing evidence on the outcomes of multidrug-resistant and extensively drug-resistant tuberculosis patients treated early (≤4 weeks) versus late (\>4 weeks) after the diagnosis of drug resistance. This review contributes to the evidence base for the generation of an updated World Health Organization (WHO) guideline for the clinical management of MDR-TB and XDR-TB.

Methods {#Sec2}
=======

PICOT Question {#Sec3}
--------------

The full original protocol and PRISMA checklist \[[@CR4]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S1) are available in the supporting information [additional file](#Sec13){ref-type="sec"} section. The following amendments or clarifications were made to the original protocol: searching Google Scholar in place of Google, including a limit of publication since 1990, including a 10 % check of sifting by a third reviewer, and allowing a flexible cut-off during sifting in the definition of the timing of early versus late treatment.

The research question was framed using PICOT (Population, Intervention, Comparison, Outcome and Time) methodology \[[@CR5], [@CR6]\]. The population under consideration was all patients with multidrug-resistant or extensively drug-resistant tuberculosis bacteriologically confirmed by phenotypic methods, or for whom molecular testing indicating rifampicin resistance was used as a surrogate for initiation of MDR treatment. The intervention and comparator of interest were early versus late treatment, defined respectively as drug treatment initiated within 28 days versus later than 28 days after diagnosis of MDR-TB. The primary outcomes in this review were the WHO-defined tuberculosis outcomes as proposed by Laserson et al. \[[@CR7]\]: cure, treatment completion, failure/relapse, transfer out, abandoned treatment and death. Treatment success was defined as patients meeting the outcome definition of cure or treatment completed. Poor outcomes were defined as patients with the outcome of failure/relapse, transfer out, abandoned treatment or death. Secondary outcomes pre-defined in the protocol were not included in the search terms, but were intended for consideration during data extraction from included papers, and were defined as adverse reactions from TB drugs (severity, type, organ class), adherence to treatment, or treatment interruption due to non-adherence.

Search strategy {#Sec4}
---------------

A comprehensive search strategy was developed in consultation with WHO technical experts using the PICOT question as a framework (see Additional file [1](#MOESM1){ref-type="media"}). Due to the relatively low number of total hits in preliminary searches, only population and intervention terms were used in the search strategy (Additional file [1](#MOESM1){ref-type="media"}: Table S2). By checking for comparator and outcomes defined a priori during the manual sift instead of in the search strategy, the likelihood of missing a potentially relevant paper was reduced. An example of the search strategy, in this case as applied in PubMed, is included in Additional file [1](#MOESM1){ref-type="media"}: Table S2.

Electronic health care databases, sources of evidence-based reviews, guidelines, and grey literature were searched in accordance with the specifications of each database. These included PubMed (including MEDLINE), EMBASE, Cochrane library (includes CENTRAL, CDSR, DARE and HTA databases), WHO Global Index Medicus (includes LILACS, WPRIM, IMSEAR, IMEMR, AIM, SciELO and WHOLIS indexes), WHO portal of clinical trials, OpenSIGLE, International Union of Tuberculosis and Lung Disease conference abstracts (2004--2014) and Google Scholar (limited to the first ten pages). The search strategies were executed on 26th September 2015. The date, human studies and language inclusion criteria were applied in the manual sifting process instead of through the limits function of PubMed (and other databases) in order to avoid exclusion of papers that had not been indexed on these criteria (Table [1](#Tab1){ref-type="table"}).Table 1Summary of non-PICO inclusion criteriaLimit categorySpecified limitImplementationLanguagesEnglish, Japanese, Chinese, Russian, French, Spanish, Portuguese, Ukrainian, LithuanianManual siftingPublication typeNonen/aDate of publication1st January 1990--26th Sept 2015Manual siftingStudy designConsecutive Case Series, Case Control Studies, Cohort Studies, Randomised Controlled Trials, Systematic Reviews and Meta-analysesManual siftingOther limitsNonen/a

Manual sifting {#Sec5}
--------------

Following removal of duplicates, two-stage screening against inclusion and exclusion criteria was executed independently by two reviewers (JN, AM), sifting first by title and abstract, followed by full-text sifting. A third reviewer (DM) reviewed any discrepant results and every tenth reference to adjudicate and check for consistency. Studies including participants of any age with confirmed multi-drug resistant or extensively drug-resistant pulmonary tuberculosis were potentially eligible for inclusion. Any consecutive case series, case control study, cohort study, randomised controlled trial, systematic review or meta-analysis that included a comparator group was considered for inclusion. Included studies were required to report data on at least one of the primary outcome measures of interest. Although the original intervention of interest was defined as presumed adequate treatment initiated ≤28 days after diagnosis, and a comparator group with treatment initiated \>28 days after diagnosis, the protocol was changed to allow flexibility in the definition of this cut off for early versus late treatment. Therefore studies reporting outcomes for patient groups with different definitions for delay to treatment initiation were considered for inclusion.

Any systematic review superseded by an updated systematic review, or narrative reviews not adding new data or new analysis to the existing evidence base were excluded. Finally, studies not performed in humans, written in a language other than those listed in Table [1](#Tab1){ref-type="table"}, or with fewer than ten participants were excluded.

Sifting was primarily managed within Endnote® X7.4 (Thomson Reuters, California, USA). If a paper was deemed ineligible for inclusion at the full text sifting stage, the primary reason for ineligibility was recorded by the reviewers.

Supplementary review and data extraction {#Sec6}
----------------------------------------

An additional post-hoc review of those articles included in the full text review was undertaken by one reviewer (DM) using alternative, less-stringent inclusion criteria. Specifically, papers were identified which reported on two or more groups of patients with different times to MDR treatment initiation. Data on treatment outcome according to WHO criteria or on intermediate outcomes such as culture conversion time (though not validated as surrogates of treatment outcome) were abstracted from papers included in this post-hoc review.

Results {#Sec7}
=======

A total of 1978 citations were retrieved from the initial search of all databases. Breakdown by database source is provided in Additional file [1](#MOESM1){ref-type="media"}: Table S3. After removal of duplicates (*n* = 475) and pre-1990 publications (*n* = 28), 1475 unique citations remained. 1411 hits were excluded during title and abstract screening. Sixty-four references were thus identified for full text review and all were retrieved \[[@CR3], [@CR8]--[@CR70]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart summarising search results

On full text review none of the 64 references fulfilled the per-protocol inclusion criteria. Reasons for exclusion are indicated in Fig. [1](#Fig1){ref-type="fig"}.

The most frequent reason for exclusion was the lack of a comparator group (91 % of full texts reviewed). Papers often reported average time to treatment, but did not disaggregate outcomes by timing of treatment, even with the more relaxed early versus late definition (not requiring a 28 day cut-off). Three narrative reviews were excluded as no new data were presented in addition to not meeting other inclusion/exclusion criteria for this review, two research articles were excluded as there were no reported outcomes of interest, and one reported on fewer than ten participants.

Supplementary post-hoc review {#Sec8}
-----------------------------

Although the full text review failed to deliver any publications fulfilling the inclusion criteria it was noted that a number of articles reported less well defined data on treatment delay (without a 28 day cut-off) related to some interim outcome measures (smear and culture conversion) and final treatment outcomes \[[@CR11], [@CR13], [@CR22], [@CR31], [@CR37], [@CR38], [@CR45], [@CR46], [@CR48], [@CR50], [@CR51], [@CR61], [@CR63], [@CR64], [@CR66], [@CR68]\].

None of these articles addressed the independent effect of treatment delay with a meaningful comparator group - whether not delayed or less delayed - upon treatment outcomes, whether interim or final.

Whilst outside the designated protocol we proceeded to abstract these data in case the resulting narrative yielded any information of use. These data and narrative summary are reported in Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: supplementary text.Table 2Supplementary post-hoc review dataAuthorJournalYearExposureOutcomeCommentsGoble \[[@CR38]\]NEJM1993Duration of diseaseFailure: continually positive sputum cultures after at least three months of therapyDuration of disease very long1-3 yrs12/444-8 yrs18/44 OR 1.8 (0.6-5.4)≥9 yrs17/46 OR 1.6 (0.5-5.0)Chan \[[@CR37]\]AJRCCM2004Each additional year delay before first visit to siteInitial favourable response: ≥3 negative sputum cultures over ≥3 months\
OR 0.93 (0.87-0.995) p=0.03Median pre-therapy disease duration = 4.2 years; analysis takes no account of time to MDR therapy, just time to first visitBonilla \[[@CR66]\]PLoS ONE2008Treatment successPaper mainly about individualisation of regimens with DST and availability of 2^nd^ line DST within 31 days; no data on lead-in time from diagnosis and exclusions from primary analyses limit interpretationMDR DST available within ≤31 days264/334 (79.0%)MDR DST available after \> 31 days108/160 (67.5%)XDR DST available within ≤31 days11/14 (78.6%)XDR DST available after \> 31 days7/23 (30.4%)Dheda \[[@CR31]\]Lancet2010Treatment outcomeDelay to treatmentCompared delay to treatment in groups of survivors and non-survivors and culture converters and non-converters.\
Delay to treatment = time from sputum acquisition to start of treatmentSurvival78 days \[53--107\]Death57 days \[36--67\]\
p=0·001Culture conversion91 days \[61--116\]Non-conversion59 days \[43--86\]\
p=0·001Heller \[[@CR45]\]IJTLD2010Median days (95%CI) treatment delayBefore vs. after comparison following change from traditional hospital based management (TM) to community based (CM).\
In multivariate analysis time to smear conversion was longer for TM group than for CM group (aHR=1.78, p=0.062), as was time to culture conversion (aHR=1.82, p=0.026)Traditional (n=46)106.5 (88.6-151.1)Community (n=48)84 (78.7-93.3) p=0.002Median days (95%CI) to smear conversionTraditional (n=48)91 (72.2-119.8)Community (n=32)59 (34.9-83.1) p=0.055Median days (95%CI) to culture conversionTraditional (n=53)119 (106.1-131.9)Community (n=39)85 (68.0-102.0)\
p=0.002Active and on treatment at 6 monthsTraditional91.2%Community84.8%\
p=0.4Seddon \[[@CR64]\]CID2012Treatment delay\
(not defined)Not associated with:\
\[1\] failure to culture convert by month 2\
(26/74, p=0.25)\
\[2\] unfavourable treatment outcome\
(15/103, p=0.36)\
\[3\] death\
(8/103, p=0.18)Median delay 91 days (IQR 51--166)\
Data in table 4 -- analysis not clearVan der Walt \[[@CR13]\]ERJ (Conference abstract)2012Time to treatmentShorter time to treatment in inpatients but no differences in time to smear or culture conversionInpatients76 daysCommunity64 days p\<0.01Sputum conversionInpatients54%Community52%Time to conversion (median with IQR)Inpatients105 (64.5-164)Community121 (61.0-206.5)Loveday \[[@CR46]\]IJTLD2012Median (IQR) treatment delay in daysDecentralised vs. centralised hospital care. Shorter delay to treatment but worse treatment outcomes for decentralised care, but many other differences in care beyond treatment initiation delay.Decentralised72 (56--99)Centralised93 (71--120)\
p\<0.001Unsuccessful treatment outcomesDecentralised96/419 (23%)Centralised37/441 (8%)Cox \[[@CR63]\]IJTLD2014Median (IQR) treatment delay in daysMDR programme implemented. But changes other than treatment initiation delay e.g. change to include moxifloxacinBefore (2005)58 (25--91) (n=39)During (2010)31 (18--45) (n=183)Treatment successBefore (2005--7)85/206 (41%)During (2010)86/164 (52%)Mpagama \[[@CR48]\]PLoS ONE2013Median (range) time from MDR diagnosis to treatmentOutcomeNo difference in time from MDR diagnosis to treatment initiation between intensive phase completers and deaths.272 (26--888)Completion of intensive phase n=54255 (193--317)Died n=4\
p=0.8Chan \[[@CR50]\]PLoS ONE2013DelayTreatment success in 3 models\
Multiple logistic analysisChange to programme management in Taiwan\>120 days133/194 (69%)≤120 days328/457 (72%)\>120 vs.≤120OR 1.2 (0.8-1.7), p=0.4\
Adjusted HRs\
0.8 (0.6-0.9), p=0.012\
0.8 (0.6-1.0), p=0.018Delay in 390 patients with second line drug susceptibility testing\>120 days74/117 (63%)≤120 days170/273 (62%)\>120 vs. ≤120OR 1.0 (0.6-1.5), p=0.9\
aOR 0.6 (0.4-0.9), p=0.01Helbling \[[@CR61]\]Swiss Med Wkly2014Time to treatmentTreatment success\
39/51 (76.5%)\
Time to treatment initiation not associated with treatment success in logistic regression model (no data shown)Median time to initiation was 5.5 weeks but 10 initiated MDR treatment immediatelyKipiani \[[@CR68]\]CID2014Line probe assay implementationDelay to MDR treatmentBefore vs. after analysis of line probe assay implementation. Groups differed in many ways -- post implementation group had more HCV co-infection, more initial inpatient treatment, more likely to receive kanamycin instead of capreomycin, higher rates on prior MDR treatment, resistant to more drugs.Pre-implementation83.9 (56--106)Post-implementation18.2 (11--24) p\<0.01\
(Unclear if overall or just for subset who received first line drugs)12 wk culture conversionPre-implementation5/68 (7%)Post-implementation25/51 (49%)24 week culture conversionPre-implementation43/68 (63%)Post-implementation44/51 (86%)\
p=0.0124 week smear conversionPre-implementation77%Post-implementation90%\
p=0.05Li \[[@CR51]\]Lancet Global Health2015Programme implementationMedian \[IQR\] time to treatmentTime to treatment only reported for 32% and 71% of pre- and post-intervention patientsBefore139 \[69--207\]After14 \[10--21\]Still on treatment at 6 monthsBefore8% (2/26)After80% (137/172)Loveday \[[@CR11]\]IJTLD2015Median (IQR) treatment delay in daysIncludes all of Loveday 2012 data plus data for 7 additional monthsDecentralised72 (54--97) (n=724)Decentralised72 (54--97) (n=724)Centralised92 (69--120) (n=811)\
p\<0.001Treatment successDecentralised427/736 (58%)Centralised439/813 (54%) p=0.18DeathDecentralised133/736 (18.1%)Centralised113/813 (13.9%) p=0.21Otero \[[@CR22]\]TMIH2015Treatment outcomesMedian (IQR) time in days to MDR-TB treatmentShould be noted that the duration of treatment prior to switching was undetermined.For patients starting on MDR regimen:Success26 (18--41)Not success25 (18--30) p=0.6For patients switching to MDR regimen:Success11.5 (2--35)Not success22 (2--48) p=0.1

Discussion {#Sec9}
==========

Whilst there is an inherent logic in the theory that treatment delay will lead, via more severe disease, to worse treatment outcomes, we were unable to find any published evidence to support this assumption. More pertinently, there were no published data demonstrating an independent effect upon treatment outcome of earlier initiation of therapy following MDR diagnosis.

It is unfortunate that such data do not exist, as evidence highlighting a clear direct benefit upon patient-centred outcomes could have provided a powerful tool to advocate for specific interventions to improve linkage of MDR diagnosis to initiation of treatment, a particular problem for countries facing growing "waiting lists" of patients diagnosed with MDR-TB awaiting health system capacity to deliver treatment, or with considerable loss to follow up between testing and initiation of treatment. This systematic review found a lack of data rather than a lack of effect, therefore it should not be assumed that there is no benefit of early access to treatment. However, a recent systematic review evaluating the potential benefit of active case finding upon treatment outcomes for drug susceptible TB failed to demonstrate any improvement over passive case finding, despite the tendency of active case finding to find cases earlier and with reduced disease severity \[[@CR71]\].

Regardless, beyond the effect for the individual, earlier treatment initiation should de facto result in reduced duration of infectiousness and thus result in reduced transmission at a community level. Treatment for MDR-TB should clearly be initiated at the earliest opportunity after diagnosis.

A major obstacle in this review was the lack of suitable comparator group, as no studies reported treatment outcomes for otherwise similar patient groups varying only the time to treatment. Where outcome data were reported related to time to treatment, it was often confounded by simultaneous changes in other elements of healthcare delivery, such as programmatic changes related to delivery of care and altered drug regimens. Therefore, it was impossible to attribute differential outcomes to treatment delay.

The authors believe that further research with time to treatment as the primary research question should not be considered a high priority amongst competing demands upon limited resources. However, improved data collection and reporting of patient outcomes by time to treatment initiation should be encouraged in studies collecting data on the outcomes of interest in this patient group. Such data could provide important insight without cost implications.

Even if such data were available, treatment delay when defined as the interval from MDR diagnosis to treatment fails to take account of delays in reaching an MDR diagnosis, the effect of which might overwhelm any potential benefit of reduced diagnosis-to-treatment time. Roll-out of new rapid diagnostics, whether molecular tests such as Xpert MTB/RIF or Genotype MTB DR-plus or direct phenotypic tests such as MODS or the nitrate reductase assay, is designed to reduce such delays through improved access and faster laboratory turnaround. Data comprehensively demonstrating an effect upon outcome of shortened time to MDR diagnosis are still awaited.

Conclusion {#Sec10}
==========

There is currently no published evidence available to assess the effect of early versus late treatment initiation upon the outcomes of patients treated for MDR-TB or XDR-TB. Whilst supportive evidence would have provided a useful advocacy tool, we feel that the intuitive logic and inherent biological plausibility mean that MDR treatment should be initiated promptly. Initiating primary research for this research question is not considered a priority amongst competing demands upon limited resources. However, improved collection of data on time to treatment initiation and treatment outcomes within other studies could provide insight into this question.
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No data were identified for inclusion in the main review. The dataset supporting the post-hoc review in this article is included within the article in Table [2](#Tab2){ref-type="table"} and in the Additional file [1](#MOESM1){ref-type="media"}: supplementary text.
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===============

Additional file 1: Table S1.PRISMA checklist. **Table S2**: Search terms applied in PubMed. **Table S3**: Number of search hits by database source. Supplementary post-hoc review text. (DOCX 139 kb)
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PICOT

:   population, intervention, comparison, outcome and time

TB
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:   World Health Organization

XDR-TB
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